Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Athira Pharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES WHITE ROCK, BRITISH COLUMBIA / ACCESS NEWSWIRE / DECEMBER 19, 2025 / ATHENA GOLD CORPORATION (CSE:ATHA)(OTCQB:AHNRF) ("ATHENA GOLD" OR THE "COMPANY") IS PLEASED TO ANNOUNCE THAT, FURTHER TO ITS NEWS RELEASES OF NOVEMBER 17, NOVEMBER 24, DECEMBER 9, AND DECEMBER 15, 2025, THE COMPANY HAS CLOSED THE THIRD AND FINAL TRANCHE OF ITS PRIVATE PLACEMENT FINANCING (THE "OFFERING") AND HAS RECEIVED PROCEEDS OF CDN $502,002.98 THROUGH THE ISSUANCE OF 7,142,900 FLOW-THROUGH UNITS (THE "FT UNITS") AT CDN $0.07 PER FT UNIT AND 33,333 NON-FLOW-THROUGH UNITS (THE "NFT UNITS") AT CDN $0.06 PER NFT UNIT. A TOTAL OF CDN $3,500,028.99 WAS RAISED IN THE OFFERING, OF WHICH CDN $2,727,526.03 WAS RAISED IN THE FIRST TRANCHE, CDN $270,499.98 IN THE SECOND TRANCHE AND CDN $502,002.98 IN THE THIRD TRANCHE.

ATHENA GOLD FULLY FUNDED FOR DRILLING WITH $3.5 MILLION NON-BROKERED PRIVATE PLACEMENT COMPLETE

PHASE 3 DEVELOPMENT PROGRAM OF NOVEL SELECTIVE ESTROGEN RECEPTOR MODULATOR (SERM) REPRESENTS POTENTIAL MULTI-BILLION DOLLAR OPPORTUNITY AS TREATMENT OPTION FOR PATIENTS WITH ESR1-MUTATIONS

ATHIRA PHARMA ANNOUNCES EXCLUSIVE LICENSE TO LASOFOXIFENE PHASE 3 DEVELOPMENT PROGRAM FOR METASTATIC BREAST CANCER CANDIDATE AND A FINANCING FOR UP TO $236 MILLION

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES WHITE ROCK, BRITISH COLUMBIA / ACCESS NEWSWIRE / DECEMBER 15, 2025 / ATHENA GOLD CORPORATION (CSE:ATHA)(OTCQB:AHNRF) ("ATHENA GOLD" OR THE "COMPANY") IS PLEASED TO ANNOUNCE THAT, FURTHER TO ITS NEWS RELEASES OF NOVEMBER 17, NOVEMBER 24 AND DECEMBER 9, 2025, THE COMPANY HAS CLOSED THE SECOND TRANCHE OF ITS PRIVATE PLACEMENT FINANCING (THE "OFFERING") AND HAS RECEIVED PROCEEDS OF CDN $270,499.98 THROUGH THE ISSUANCE OF 150,000 FLOW-THROUGH UNITS (THE "FT UNITS") AT CDN $0.07 PER FT UNIT AND 4,333,333 NON-FLOW-THROUGH UNITS (THE "NFT UNITS") AT CDN $0.06 PER NFT UNIT. AN AGGREGATE OF CDN $2,727,526.03 WAS RAISED IN THE FIRST TRANCHE OF THE OFFERING.

ATHENA GOLD CLOSES SECOND TRANCHE OF NON-BROKERED PRIVATE PLACEMENT AND INCREASES OFFERING DUE TO STRONG DEMAND

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES WHITE ROCK, BC / ACCESS NEWSWIRE / DECEMBER 9, 2025 / ATHENA GOLD CORPORATION (CSE:ATHA)(OTCQB:AHNRF) ("ATHENA GOLD" OR THE "COMPANY") IS PLEASED TO ANNOUNCE THE CLOSING OF THE FIRST TRANCHE OF A NON-BROKERED PRIVATE PLACEMENT PREVIOUSLY ANNOUNCED ON NOVEMBER 14, 2025, AS AMENDED NOVEMBER 24, 2025, TO RAISE UP TO CDN $3,100,000 (THE "OFFERING"). AN AGGREGATE OF CDN $2,727,526.03 HAS BEEN RAISED IN THE FIRST TRANCHE CONSISTING OF THE FOLLOWING: CDN $1,331,801.03 THROUGH THE ISSUANCE OF 19,025,729 FLOW-THROUGH UNITS (THE "FT UNITS") AT A PRICE OF CDN $0.07 PER FT UNIT; CDN $1,015,500.08 THROUGH THE ISSUANCE OF 14,507,144 FLOW-THROUGH COMMON SHARES (THE "CMETC FT SHARES) AT A PRICE OF CDN $0.07 PER CMETC FT SHARE; AND CDN $380,224.92 THROUGH THE ISSUANCE OF 6,337,082 NON-FLOW-THROUGH UNIT (THE "NFT UNITS") AT A PRICE OF CDN $0.06 PER NFT UNIT.

ATHENA GOLD CLOSES FIRST TRANCHE OF NON-BROKERED PRIVATE PLACEMENT AND ANNOUNCES FURTHER UPSIZE

MAIDEN DIAMOND DRILLING RETURNS 4.33 G/T AU OVER 14.4M; GEOPHYSICS DEFINES LARGE INTRUSIVE WHITE ROCK, BC / ACCESS NEWSWIRE / NOVEMBER 26, 2025 / ATHENA GOLD CORPORATION (CSE:ATHA)(OTCQB:AHNRF) ("ATHENA" OR THE "COMPANY") IS PLEASED TO PROVIDE AN EXPLORATION UPDATE FROM ITS EXCELSIOR SPRINGS PROJECT IN NEVADA. MAMMOTH MINERALS LIMITED (ASX:M79) (FORMERLY FIRETAIL RESOURCES LIMITED) HAS BEEN AGGRESSIVELY EXPLORING EXCELSIOR, PER ITS OPTION AGREEMENT TO EARN AN 80% INTEREST IN THE PROJECT OVER FIVE YEARS, PROVIDING ATHENA A FREE-CARRY TO DEFINITIVE FEASIBILITY STUDY THEREAFTER (SEE PRESS RELEASES DATED JUNE 2, 2025, AND AUGUST 22, 2025).

ATHENA GOLD PROVIDES EXPLORATION UPDATE FROM EXCELSIOR GOLD-SILVER PROJECT, NEVADA

HIGHLIGHTS ASSAYS CONFIRM THE COMPANY'S MAIDEN DRILLHOLE, RIBN-DD-001, AT THE RIB NORTH DISCOVERY AS THE BEST EXPLORATION HOLE DRILLED TO DATE AT THE ANGILAK URANIUM PROJECT; RIBN-DD-001 ASSAYS RETURNED TOTAL COMPOSITE URANIUM MINERALIZATION1 OF 34.7 M ENCOMPASSING SEVEN ZONES FROM 287.0 M TO 439.9 M (FIGURE 4) - SURPASSING WHAT WAS REPORTED IN THE RELEASE OF PRELIMINARY RESULTS (SEPTEMBER 23RD, 2025, NEWS RELEASE ); THE WIDEST CONTINUOUS INTERSECTION IN THE HOLE - FROM 426.3 TO 439.9 - RETURNED 13.6 M OF COMPOSITE URANIUM MINERALIZATION1 GRADING 0.53% U3O8, INCLUDING 1.1 M GRADING 4.81% U3O8 WITH THE HIGHEST-GRADE SAMPLE RETURNING 8.16% U3O8 OVER 0.5 M; MINERALIZATION WAS FIRST INTERSECTED IN THE SANDSTONE OVER THREE INTERVALS (BETWEEN 287.0 M AND 351.1 M). THE FOURTH ZONE WAS INTERSECTED DIRECTLY ABOVE THE UNCONFORMITY (LOCATED AT 356.7M), EXTENDING INTO GRAPHITIC BASEMENT ROCK BELOW.

ATHA ENERGY CONFIRMS NEW HIGH-GRADE DISCOVERY AT ANGILAK PROJECT - RIB NORTH, MAIDEN HOLE RETURNS ASSAYS WITH 34.7 M OF TOTAL COMPOSITE URANIUM MINERALIZATION, INCLUDING 13.6 M GRADING 0.53% U3O8, 1.1 M GRADING 4.81% U3O8, AND GRADES UP TO 8.16% U3O8

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BRITISH COLUMBIA / ACCESS NEWSWIRE / OCTOBER 31, 2025 / ATHA ENERGY CORP. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" OR THE "COMPANY"), IS PLEASED TO ANNOUNCE THAT, FURTHER TO ITS PRESS RELEASE DATED OCTOBER 21, 2025, THE COMPANY HAS FILED ITS FINAL SHORT FORM PROSPECTUS (THE "PROSPECTUS") WITH THE SECURITIES COMMISSIONS IN BRITISH COLUMBIA, ALBERTA, SASKATCHEWAN, MANITOBA, ONTARIO AND NEW BRUNSWICK AND BEEN ISSUED A RECEIPT (THE "RECEIPT") BY THE BRITISH COLUMBIA SECURITIES COMMISSION, AS PRINCIPAL REGULATOR, IN CONNECTION WITH THE QUALIFICATION OF UP TO 18,838,752 UNITS (THE "UNITS") OF THE COMPANY ISSUABLE UPON THE EXERCISE OR DEEMED EXERCISE OF 17,126,138 SPECIAL WARRANTS ("SPECIAL WARRANTS") OF THE COMPANY ISSUED IN CONNECTION WITH ITS PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT.

Athira Pharma, Inc.

ATHA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Athira Pharma, Inc.

ATHA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ATHA